The approach is generic. The implementation is case by case. But this is exactly the problem. When the implementation is generic, like a vaccine, then you can mass produce it and the costs go down.

As far as this seems, you can’t mass produce this solution. You can mass implement the approach, but that doesn’t really bring the cost down.